High materiality8/10
Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?
Why it may matterVerify against the original reporting
The results were inconclusive, leading to a significant stock drop.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Galectin's belapectin showed 43.2% varices reduction but lacked statistical significance. In a per-protocol analysis, varices reduction reached 48.9%, slightly below expectations. Full NAVIGATE trial data analysis is ongoing; updates expected in early 2025. GALT stock dropped 59% to $0.80 following the trial results.
- Galectin's belapectin showed 43.2% varices reduction but lacked statistical significance.
- In a per-protocol analysis, varices reduction reached 48.9%, slightly below expectations.
- Full NAVIGATE trial data analysis is ongoing; updates expected in early 2025.
- GALT stock dropped 59% to $0.80 following the trial results.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.